Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) Shares outstanding
Vertex Pharmaceuticals Incorporated's shares outstanding at the end of fiscal 2025 was $258.0M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $255.2M. Over the past ten years it has ranged from $241.3M (fiscal 2015) to $263.4M (fiscal 2020); the current reading is higher than 45% of that period. Vertex Pharmaceuticals Incorporated ranks 29th of 604 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Annual
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $258.0M | 0.04% |
| FY2024 | $257.9M | (1.00%) |
| FY2023 | $260.5M | 0.54% |
| FY2022 | $259.1M | (0.31%) |
| FY2021 | $259.9M | (1.33%) |
| FY2020 | $263.4M | 1.04% |
| FY2019 | $260.7M | 0.58% |
| FY2018 | $259.2M | 2.35% |
| FY2017 | $253.2M | 3.49% |
| FY2016 | $244.7M | 1.40% |
Quarterly
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $255.2M | (0.43%) |
| Mar 2026 | $256.3M | (0.66%) |
| Dec 2025 | $258.0M | 0.16% |
| Sep 2025 | $257.6M | (0.50%) |
| 42 more quarters | Free account |
Against its own ten years
Low $241.3M
High $263.4M
Ten-year median
$259.1M
Current reading's percentile
45
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RPRX Royalty Pharma PLC compare | $556.9M |
| MRNA Moderna, Inc. compare | $398.0M |
| VRTX Vertex Pharmaceuticals Incorporated | $255.2M |
| INSM Insmed, Inc. compare | $217.4M |
| RVMD Revolution Medicines, Inc. compare | $210.9M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.3M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
| REGN Regeneron Pharmaceuticals, Inc. compare | $106.0M |
| ARGX argenex SE compare | $64.5M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- The full statement